FWBI Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 163228 min ago

@ $5.43

Ausgestellt: 9 Feb 2024 @ 21:55

Rendite: -45.49%

Vorheriges Signal: Feb 7 - 20:00

Vorheriges Signal: Verkaufen

Rendite: 5.44 %

Live Chart Being Loaded With Signals

Commentary (16 Mai 2024 @ 22:00):

Stats
Tagesvolumen	56 362.00
Durchschnittsvolumen	72 481.00
Marktkapitalisierung	5.99M
EPS	$0 ( 2024-05-12 )
Nächstes Ertragsdatum	( $-1.670 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600
ATR14	$0.0430 (1.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Sapirstein James	Sell	174	Common Stock
2024-04-01	Romano Sarah	Sell	75	Common Stock
2024-03-15	Sapirstein James	Sell	1 887	Common Stock
2024-03-15	Romano Sarah	Sell	1 120	Common Stock
2024-03-13	Syage Jack	Buy	15 400	Common Stock, par value $0.0001 per share

INSIDER POWER
93.41
Last 95 transactions
Buy: 5 900 618 \| Sell: 1 318 677

Volumen Korrelation

Lang: -0.13 (neutral)

Kurz: 0.62 (weak)

Signal:(57.52) Neutral

First Wave BioPharma, Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

First Wave BioPharma, Korrelation - Währung/Rohstoff

-0.17
( neutral )

0.10
( neutral )

0.00
( neutral )

-0.15
( neutral )

-0.47
( neutral )

0.53
( weak )

First Wave BioPharma, Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-29 274.00 (0.00 %)
EPS:	$-46.96

FY	2023
Umsatz:	$0
Bruttogewinn:	$-29 274.00 (0.00 %)
EPS:	$-46.96

FY	2022
Umsatz:	$0
Bruttogewinn:	$-106 207 (0.00 %)
EPS:	$-461.72

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1 377.25

Financial Reports:

No articles found.

First Wave BioPharma, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

First Wave BioPharma,

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.